Early increase of CD103 expression on peripheral PD-1+ CD8+ T cells predicts response to nivolumab in advanced esophageal squamous cell carcinoma [0.03%]
外周PD-1+CD8+T细胞早期CD103表达增加可预测食管鳞癌患者纳武利尤单抗治疗疗效
Satoko Sumimoto,Tomoki Makino,Shigeto Nakai et al.
Satoko Sumimoto et al.
Background: Nivolumab has become a standard treatment for advanced or recurrent esophageal squamous cell carcinoma (ESCC). However, reliable blood-based biomarkers predictive of response remain undefined. We investigated ...
Decoding circulating neutrophil phenotypes in triple-negative breast cancer via optimized single-cell RNA sequencing [0.03%]
通过优化的单细胞RNA测序解析三阴性乳腺癌循环中性粒细胞表型
Marcin Banacki,Krzysztof Pastuszak,Michał Sieczyński et al.
Marcin Banacki et al.
Neutrophils are emerging as key regulators of tumor biology, influencing cancer progression, immune evasion, and therapeutic response. However, their transcriptomic characterization remains challenging due to low RNA content, limiting confi...
Katherine Lei,Meera J Patel,Jialiang Liu et al.
Katherine Lei et al.
Seasonal variation in immune-related adverse events in advanced cancer patients [0.03%]
晚期癌症患者免疫相关不良事件的季节性变化
Roger Liang,Bo Gao,Adnan Nagrial et al.
Roger Liang et al.
Background: Immune checkpoint inhibitors (ICIs) improve outcomes across advanced cancers but can cause immune-related adverse events (irAEs). Seasonal environmental factors influence immune regulation and autoimmunity, ye...
NY-ESO-1 and PD-L1 as biomarkers associated with nivolumab response and outcome in unresectable or recurrent esophageal squamous cell carcinoma: a multicenter biomarker study [0.03%]
纽约腺相关抗原-1和程序性死亡配体1作为预测不可切除或复发性食管鳞癌尼伏单抗疗效的生物标志物：一项多中心生物标记物研究
Shigeto Nakai,Tomoki Makino,Kota Momose et al.
Shigeto Nakai et al.
Background: Programmed cell death protein-1 (PD-1) blockade improves survival in esophageal squamous cell carcinoma (ESCC), although only a subset of patients respond. We aimed to identify tumor-related biomarkers associa...
Mechanical preconditioning by shear stress enhances memory formation and anti-tumor function of CAR-T cells [0.03%]
剪切应力预激活CAR-T细胞增强其抗肿瘤记忆功能
Lianfeng Zhao,Jiaqi Liu,Yan Zhang et al.
Lianfeng Zhao et al.
Chimeric antigen receptor T-cell (CAR-T) therapy has achieved remarkable success in the treatment of hematological malignancies, and its application to solid tumors is currently under active investigation. Upon infusion into the bloodstream...
Broader gene representation by whole-exome sequencing improves accuracy of tumor mutational burden assessment for selection of pembrolizumab immunotherapy [0.03%]
全外显子组测序改善肿瘤突变负荷评估的准确性以选择派姆单抗免疫治疗
Milan Radovich,James Wacker,Jeffrey Solzak et al.
Milan Radovich et al.
Although the tissue-agnostic FDA approval of pembrolizumab for tumor mutational burden (TMB)-high tumors has provided meaningful clinical benefit to patients, there remains a need to optimize TMB assessment. In this cohort study, we investi...
Cabozantinib and atezolizumab for recurrent or metastatic esophageal squamous cell carcinoma after platinum-based chemotherapy failure: a single-arm phase II study and biomarker analysis [0.03%]
卡博替尼联合阿特朱单抗治疗铂类化疗失败的复发或转移性食管鳞癌：一项单臂Ⅱ期临床研究及其生物标志物分析
Hung-Yang Kuo,Ta-Chen Huang,Chien-Huai Chuang et al.
Hung-Yang Kuo et al.
Purpose: Anti-PD-1 immune-checkpoint inhibitors (ICIs) are approved for treating patients with recurrent or metastatic (R/M) esophageal squamous cell carcinoma (ESCC) who have failed platinum-based chemotherapy. However, ...
β-elemene enhances the efficacy of PD-L1 inhibitor in lung cancer by reprogramming tumor-associated macrophages to M1 phenotype via suppressing FLT1/PI3K/AKT signaling [0.03%]
β-艾叶素通过抑制FLT1/PI3K/AKT信号重编肿瘤相关巨噬细胞为M1表型从而增强PD-L1抑制剂在肺癌中的疗效
Jianmin Wang,Yongxin Yu,Fenglin Lin et al.
Jianmin Wang et al.
Immune checkpoint inhibitors (ICI), epitomized by PD-1/PD-L1 antibodies, have ushered in a new era in lung cancer treatment. However, ICI monotherapy is only applicable to a small subset of patients with high PD-L1 expression, while most pa...
Novel recombinant protein PK5-Gal-3C enhances the anti-tumor activity of T cells via binding with TRPV2 [0.03%]
新型重组蛋白PK5-Gal-3C通过结合瞬时受体电位香草素子通道2增强T细胞的抗肿瘤活性
Guopeng Zhang,Wei Zhang,Xiaohuan Wei et al.
Guopeng Zhang et al.
Investigating strategies to enhance T cell effector function can improve the adoptive immune responses to tumors and complement existing tumor immunotherapies. Here, we present a novel artificially designed recombinant protein, PK5-Gal-3C, ...